|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||118.68 - 119.67|
|52-week range||93.13 - 130.40|
|Beta (5Y monthly)||0.19|
|PE ratio (TTM)||110.50|
|Forward dividend & yield||2.79 (2.35%)|
|Ex-dividend date||12 Aug 2021|
|1y target est||N/A|
Dr. Taison Bell, Assistant Professor of Medicine at the University of Virginia, joins Yahoo Finance Live to discuss Virginia getting rid of its mask mandate for schools, the Omicron variant, and coronavirus vaccinations.
WILMINGTON, Del., January 18, 2022--Positive results from the HIMALAYA Phase III trial showed a single priming dose of tremelimumab added to IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus sorafenib as a 1st-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment.
WILMINGTON, Del., January 18, 2022--Positive results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free survival (PFS) versus chemotherapy alone as a 1st-line treatment for patients with advanced biliary tract cancer (BTC).